It looks like Pro140 may have enough data to pursue development. But you guys are very unrealistic. First of all Breakthrough therapy designation is off the table. BT need to be approved before PH 3 trial is agreed upon. So after BLA filing there is a 60 day period for FDA to accept application and up to 12 more months till approval. Next if the Combo therapy is the first approval then less than 30% of all MDR patients can be treated by Pro 140. More than 70% may have a strain that Pro 140 is not able to treat which will be reflected in their label. So approval is not likely until late 2019 to early 2020 in US Several years later in EU. The target MFR population will be less than 10,000 patients. Still pretty good for a company with a market cap of less than $200 MM. No if Pr0 140 gets first line treatment for Mono then I think you will have a bigger opportunity, maybe likely larger than Therf. Of course more data is needed including the second part of Combo trial results.